Skip to search formSkip to main contentSkip to account menu

Wnt-5a Mimic Hexapeptide Foxy-5

Known as: Foxy-5 
A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer.
2018
2018
Targeting the Dvl-1/β-arrestin2/JNK3 interaction disrupts Wnt5a-JNK3 signaling and protects hippocampal CA1 neurons during cerebral ischemia reperfusion
Review
2017
Review
2017
Therapeutic Potential of Targeting Wnt/β‐Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress
Wnt/β‐catenin pathway is one of the main/frequent dysregulated pathways in several tumor types, including colon cancer. Aberrant… 
2017
2017
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
Prostate cancer patients with high WNT5A expression in their tumors have been shown to have more favorable prognosis than those… 
2016
2016
Non‐canonical WNT5A signaling up‐regulates the expression of the tumor suppressor 15‐PGDH and induces differentiation of colon cancer cells
2014
2014
Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer.
TPS1140 Background: The primary tumor is rarely the cause of death of cancer patients. Instead cancer-associated mortality is… 
Review
2012
Review
2012
Wnt-5a Is a Synaptogenic Factor with Neuroprotective Properties against Aβ Toxicity
Background: We have recently found that Wnt-5a regulates the synaptic structure and function in hippocampal neurons. This ligand… 
2009
2009
Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells
One third of all breast cancers are estrogen receptor alpha (ERα) negative, carry a poor overall prognosis, and do not respond… 
Review
2009
Review
2009
The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer
This article has been retracted at the request of the authors. Retraction: The WNT-5a derived peptide, Foxy-5, possesses dual… 
Highly Cited
2008
Highly Cited
2008
The Wnt-5a–Derived Hexapeptide Foxy-5 Inhibits Breast Cancer Metastasis In vivo by Targeting Cell Motility
Purpose: An inherent problem in breast cancer treatment is that current therapeutic approaches fail to specifically target the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)